wofats wrote: Basilea announces Zevtera® (ceftobiprole) marketing authorization in Brazil
Basel/Allschwil, Switzerland, July 12, 2022
Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company, announced today that its distribution partner for Latin America, Knight Therapeutics Inc. (“Knight”, TSX: GUD), has received a marketing authorization from the Agncia Nacional de Vigilncia Sanitria (Anvisa) in Brazil for the broad-spectrum, anti-MRSA (methicillin-resistant Staphylococcus aureus) antibiotic Zevtera® (ceftobiprole). Zevtera is indicated for the treatment of adult patients with community-acquired pneumonia (CAP) and adult patients with hospital-acquired pneumonia (HAP), excluding ventilator-associated pneumonia (VAP).
David Veitch, Basilea’s Chief Executive Officer, stated: “We are very pleased with the approval of Zevtera in Brazil. We look forward to working with Knight to make Zevtera available to patients in Brazil. Knight has a strong local presence in Brazil, with a track record of successfully launching anti-infective brands in the country.”
The grant of the marketing authorization triggered a milestone payment from Knight to Basilea.